Allan JN - Search Results

1

XPO1 Enables Adaptive Regulation of mRNA Export Required for Genotoxic Stress Tolerance in Cancer Cells.

Marullo R, Rutherford SC, Revuelta MV, Zamponi N, Culjkovic-Kraljacic B, Kotlov N, Di Siervi N, Lara-Garcia J, Allan JN, Ruan J, Furman RR, Chen Z, Shore TB, Phillips AA, Mayer S, Hsu J, van Besien K, Leonard JP, Borden KLB, Inghirami G, Martin P, Cerchietti L. Marullo R, et al. Among authors: allan jn. Cancer Res. 2024 Jan 2;84(1):101-117. doi: 10.1158/0008-5472.CAN-23-1992. Cancer Res. 2024. PMID: 37801604 Free PMC article.

2

Targeting metabolism and survival in chronic lymphocytic leukemia and Richter syndrome cells by a novel NF-κB inhibitor.

Vaisitti T, Gaudino F, Ouk S, Moscvin M, Vitale N, Serra S, Arruga F, Zakrzewski JL, Liou HC, Allan JN, Furman RR, Deaglio S. Vaisitti T, et al. Among authors: allan jn. Haematologica. 2017 Nov;102(11):1878-1889. doi: 10.3324/haematol.2017.173419. Epub 2017 Aug 31. Haematologica. 2017. PMID: 28860341 Free PMC article.

3

Optimal management of the young patient CLL patient.

Allan JN, Furman RR. Allan JN, et al. Best Pract Res Clin Haematol. 2018 Mar;31(1):73-82. doi: 10.1016/j.beha.2017.10.012. Epub 2017 Nov 20. Best Pract Res Clin Haematol. 2018. PMID: 29452669 Review.

4

Novel Richter Syndrome Xenograft Models to Study Genetic Architecture, Biology, and Therapy Responses.

Vaisitti T, Braggio E, Allan JN, Arruga F, Serra S, Zamò A, Tam W, Chadburn A, Furman RR, Deaglio S. Vaisitti T, et al. Among authors: allan jn. Cancer Res. 2018 Jul 1;78(13):3413-3420. doi: 10.1158/0008-5472.CAN-17-4004. Epub 2018 May 7. Cancer Res. 2018. PMID: 29735551

5

Current trends in the management of Richter's syndrome.

Allan JN, Furman RR. Allan JN, et al. Int J Hematol Oncol. 2019 Jan 8;7(4):IJH09. doi: 10.2217/ijh-2018-0010. eCollection 2018 Dec. Int J Hematol Oncol. 2019. PMID: 30651968 Free PMC article. Review.

6

It's not all about the CNS. High dose methotrexate in DLBCL.

Allan JN, Van Besien K. Allan JN, et al. Leuk Lymphoma. 2019 Aug;60(8):1845-1847. doi: 10.1080/10428194.2019.1613544. Epub 2019 May 23. Leuk Lymphoma. 2019. PMID: 31120336 No abstract available.

7

A phase I trial of palbociclib plus bortezomib in previously treated mantle cell lymphoma.

Martin P, Ruan J, Furman R, Rutherford S, Allan J, Chen Z, Huang X, DiLiberto M, Chen-Kiang S, Leonard JP. Martin P, et al. Leuk Lymphoma. 2019 Dec;60(12):2917-2921. doi: 10.1080/10428194.2019.1612062. Epub 2019 May 23. Leuk Lymphoma. 2019. PMID: 31120355 Clinical Trial.

8

Chronic lymphocytic leukemia with TP53 gene alterations: a detailed clinicopathologic analysis.

Liu YC, Margolskee E, Allan JN, Mathew S, Bhavsar E, Casano J, Orazi A, Furman RR, Geyer JT. Liu YC, et al. Among authors: allan jn. Mod Pathol. 2020 Mar;33(3):344-353. doi: 10.1038/s41379-019-0356-z. Epub 2019 Sep 2. Mod Pathol. 2020. PMID: 31477813 Free article.

9

ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patient-derived xenograft mouse models.

Vaisitti T, Arruga F, Vitale N, Lee TT, Ko M, Chadburn A, Braggio E, Di Napoli A, Iannello A, Allan JN, Miller LL, Lannutti BJ, Furman RR, Jessen KA, Deaglio S. Vaisitti T, et al. Among authors: allan jn. Blood. 2021 Jun 17;137(24):3365-3377. doi: 10.1182/blood.2020008404. Blood. 2021. PMID: 33512452 Free PMC article.

10

Outcomes in CLL patients with NOTCH1 regulatory pathway mutations.

Helbig DR, Abu-Zeinah G, Bhavsar E, Christos PJ, Furman RR, Allan JN. Helbig DR, et al. Among authors: allan jn. Am J Hematol. 2021 Jun 1;96(6):E187-E189. doi: 10.1002/ajh.26140. Epub 2021 Mar 10. Am J Hematol. 2021. PMID: 33625731 Free article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

58 results

Search Page